IntoCell, Inc. (KOSDAQ:287840)

Market Cap	443.90B
Revenue (ttm)	2.30B -20.9%
Net Income	-10.60B
EPS	-744.02
Shares Out	15.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70,870
Average Volume	82,804
Open	29,750
Previous Close	30,750
Day's Range	29,100 - 31,850
52-Week Range	17,000 - 74,900
Beta	n/a
RSI	25.94
Earnings Date	n/a

About IntoCell

IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers. In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxi...

• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 287840

Financial Performance

In 2025, IntoCell's revenue was 2.30 billion, a decrease of -20.86% compared to the previous year's 2.91 billion. Losses were -10.60 billion, 6.97% more than in 2024.